A phase IIa, randomized, double-blind, placebo-controlled, parallel group study to assess pharmacodynamics, pharmacokinetics, safety and tolerability of oral multiple ascending doses of AZD0328 in patients with schizophrenia
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2010
At a glance
- Drugs AZD 0328 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 09 Jul 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 15 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by the ClinicalTrials.gov record.
- 23 May 2008 New trial record.